How Clinical Research Sites Get Selected for Clinical Trials

Sponsors do not select sites randomly. They have a scorecard, and your site is being scored whether or not you know what the criteria are. Most sites find out they were passed over from a brief email or no reply at all. Understanding how that scorecard actually works is the difference between being invited to trials and being invisible to them.

What Sponsors and CROs Are Actually Evaluating

Every site selection process, whether run by a sponsor's clinical operations team or a CRO managing the study on their behalf, runs through a consistent set of evaluation domains. The names and weights vary by organization and protocol, but the same five categories appear in nearly every formal evaluation framework.

Patient population access is the first filter. Sponsors want to know whether your site can realistically reach the eligible patient pool for this specific protocol. That means your geographic area, your existing patient database, and your referral relationships. A site with 10,000 general cardiology patients may still fail this filter if the protocol calls for HFpEF with a documented hospitalization in the prior six months.

PI and staff experienceis the second domain. Sponsors look at the PI's publication record and protocol history in this therapeutic area. A PI who has run five Phase III oncology studies is a lower-risk bet than one whose CV shows general internal medicine without any relevant trial history.

Infrastructure and regulatory readiness covers physical space, equipment, pharmacy access, and regulatory file state. IRB membership, existing SOPs, an active FDA Form 1572 history, and dedicated research space all factor in.

Historical enrollment performance is often the most heavily weighted domain. Sponsors and CROs track site-level performance data across studies. If your site was enrolled in a prior trial in the same indication and underperformed its target, that data follows you. Sponsors access this through internal records and, increasingly, through third-party site performance databases.

Competitive trial load closes out the scorecard. A site already running four competing studies in the same therapeutic area faces capacity questions. Sponsors want to know how much attention this protocol will actually get.

Knowing the five domains matters because each one is improvable before the questionnaire arrives. Understanding why trials miss enrollment targets in the first place gives sites the right frame for this work.

The Feasibility Questionnaire Is a Test You Can Study For

Most research coordinators approach the feasibility questionnaire as an information-gathering exercise. Fill in the boxes, estimate the patient numbers, submit, and wait. That framing costs sites selection opportunities they should be winning.

The questionnaire is not information gathering. It is a scored evaluation. Every major CRO and most sponsor clinical operations teams have internal rubrics for what a "good" answer looks like in each field.

Sponsors score feasibility questionnaires across four main categories.

Running a structured feasibility assessment before the questionnaire arrives means you already have the answers. Sites that do this work in advance, rather than at the moment of the questionnaire, consistently produce stronger submissions.

Thirty-seven percent of enrolled sites underperform their own enrollment target (Credevo). The feasibility questionnaire is one of the earliest places that gap is decided.

Historical Performance Is the Strongest Signal

A new site competing against an established site faces a disadvantage that no amount of good facilities or enthusiastic staff can fully overcome. Sponsors weight historical enrollment data more than any other single factor, and for good reason: past performance in similar protocols is the best available predictor of future performance.

The metrics sponsors pull when reviewing prior performance are specific. Enrollment rate versus target is the headline number. Screen fail rate matters because it signals how well the site actually matched the protocol to its patient population. Protocol deviation frequency signals coordinator quality and training discipline. Time to first patient enrolled reflects startup efficiency.

Thirty percent of investigative sites meet their enrollment targets (Tufts CSDD). That number means two-thirds of enrolled sites have a performance record that will work against them in the next selection process.

For sites building a performance record, the path forward is consistent: deliver on the commitments you make, document your process, and build a relationship with the sponsor's CRA so performance is contextualized rather than just a number in a database.

What Gets a Site Passed Over (and Why Sponsors Never Say)

Sites that are not selected almost never find out why. The standard communication is a brief email confirming the site will not be moving forward, with no elaboration. Sponsors and CROs are under no obligation to explain, and most choose not to.

That silence makes it difficult for sites to improve. The reasons behind non-selection cluster into five patterns.

Diagnosing which factor likely applied requires honest self-assessment. If you are losing selection opportunities in narrow-eligibility indications, patient population is the most likely culprit. If you are losing studies you should be winning based on patient volume, look at IRB timelines and coordinator stability first.

How to Build a Sponsor Relationship Before the Questionnaire

The feasibility questionnaire is not the first impression. For most sites, it feels like the beginning of the process. For sponsors, it is much later.

Sponsors and CROs maintain internal awareness of sites long before a study enters the site identification phase. That awareness is built through conference relationships, CRO preferred site lists, clinical trial registry accuracy, and therapeutic area reputation.

Running an enrollment feasibility report before a study opens builds the quantified patient population data that sponsors expect in a feasibility questionnaire. Sites that can cite chart review results, referral volume data, and competitive landscape analysis stand apart from sites that estimate from memory.

Preferred Site Networks and What They Actually Require

Most major CROs maintain internal preferred site networks (PSNs). These are tiered lists of sites that have demonstrated consistent performance and operational reliability across multiple studies. Sites in a PSN skip several rounds of early-stage screening when a new study opens, which means faster selection, faster activation, and more study opportunities overall.

Getting on a preferred site network is not a formal application process in most cases. It is the result of demonstrated performance across one or more studies with that CRO.

The attributes CROs use to tier their preferred sites follow the same logic as the selection scorecard. Consistent enrollment performance relative to target. Low protocol deviation rates. Coordinator stability (the same staff on each study, which accelerates ramp-up). Reasonable budget acceptance. Responsive communication with monitors and project managers.

A practical first step is to identify which CROs are most active in your therapeutic area and ensure you have a documented, positive relationship with at least one study team within that organization. That relationship is the on-ramp to preferred site consideration.

The Site Qualification Visit: What Sponsors Check In Person

The site qualification visit (SQV) is often treated as a formality. Sites assume that if they have made it to the SQV stage, the decision is largely made. That assumption leads to avoidable losses.

The SQV is an active evaluation. Monitors arrive with a structured checklist and report back to the sponsor's clinical operations team. Four domains get the most attention.

Sites that treat the SQV as a real evaluation, and prepare accordingly, consistently activate faster and start from a stronger relationship with the study team.

How a Recruitment Partner Changes the Selection Equation

Enrollment risk is the primary reason sponsors pass on sites that otherwise qualify. A site with a strong PI, a clean regulatory history, and an appropriate patient population still carries timeline risk if the sponsor has no evidence it can actually enroll.

A site that enters a study with a contractual enrollment commitment attached, backed by a recruitment partner operating under a performance guarantee, carries demonstrably less risk. Sponsors weigh that difference in the selection process.

Clinical Enroll's model is built on a contractual randomization commitment: a specific number of randomized patients, with the campaign re-run at no charge if the target is not met. The results from published engagements reflect what this looks like in practice.

Sites working to become preferred partners can check if their current study qualifies for Clinical Enroll's recruitment support.